黄芪甲苷对神经炎症的改善作用及机制研究OA
Improvement effects and mechanism of astragaloside Ⅳ on neuroinflammation
目的 探讨黄芪甲苷对脂多糖(LPS)诱导的神经炎症的改善作用及机制.方法 将BV2细胞分为对照组、LPS组和黄芪甲苷20、40 μmol/L组以及地塞米松组(2 μmol/L),给药处理后,除对照组外其余各组加入1 μg/mL的LPS 以诱导神经炎症细胞模型,再检测各组细胞上清液中炎症因子[白细胞介素6(IL-6)、肿瘤坏死因子α(TNF-α)、一氧化氮(NO)]水平.将小鼠随机分为正常组、模型组、阳性对照组(阿司匹林肠溶片,20 mg/kg)和黄芪甲苷低、高剂量组(10、20 mg/kg),每组6只.各组小鼠灌胃/腹腔注射相应药物/生理盐水,每天1次,连续14 d.除正常组外,其余各组小鼠每天给药/生理盐水1 h后,腹腔注射LPS(250 μg/kg)建立神经炎症动物模型.末次注射LPS 2 h后,检测小鼠血清中IL-6、TNF-α水平;观察小鼠脑组织病理学形态;观察小鼠脑皮质区诱导型一氧化氮合酶(iNOS)/离子化钙结合衔接分子1(Iba1)和CD206/Iba1的共定位情况;检测小鼠脑组织中核因子κB(NF-κB)/丝裂原活化蛋白激酶(MAPK)信号通路相关蛋白[NF-κB p65、磷酸化NF-κB p65(p-NF-κB p65)、p38 MAPK、磷酸化p38 MAPK(p-p38 MAPK)、胞外信号调节激酶(ERK)、磷酸化ERK(p-ERK)]表达水平.结果 在细胞实验中,与对照组比较,LPS组细胞上清液中IL-6、TNF-α、NO水平均显著升高(P<0.05);与LPS组比较,各给药组细胞上清液中IL-6、TNF-α、NO水平均显著降低(P<0.05).在动物实验中,与正常组比较,模型组小鼠血清中IL-6、TNF-α水平和脑皮质区iNOS/Iba1共定位阳性细胞数以及脑组织中p38 MAPK、NF-κB p65、ERK蛋白的磷酸化水平均显著升高/增多(P<0.05),脑皮质区CD206/Iba1共定位阳性细胞数显著减少(P<0.05),脑皮质区和海马CA3区神经元细胞排列紊乱;与模型组比较,各给药组小鼠上述定量指标均显著逆转(P<0.05),脑皮质区和海马CA3区神经元细胞排列较为整齐.结论 黄芪甲苷可能通过抑制NF-κB/MAPK信号通路激活,促进小胶质细胞发生M2型极化,进而抑制神经炎症反应.
OBJECTIVE To investigate the improvement effects and mechanism of astragaloside Ⅳ(AS-Ⅳ)on lipopolysaccharide(LPS)-induced neuroinflammation.METHODS BV2 cells were divided into control group,LPS group,AS-Ⅳgroups at concentrations of 20 and 40 μmol/L,and dexamethasone group(2 μmol/L).Except for control group,neuroinflammation model was established with LPS(1 μg/mL)in other groups after medication.The levels of inflammatory factors[interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),and nitric oxide(NO)]in cell supernatant were measured in each group.Mice were randomly divided into normal group,model group,positive control group(Aspirin enteric-coated tablet,20 mg/kg),AS-Ⅳ low-and high-dose groups(10,20 mg/kg),with 6 mice in each group.Mice in each group were administered the corresponding drug/normal saline via gavage/intraperitoneal injection,once a day,for 14 consecutive days.Except for normal group,other groups were intraperitoneally injected with LPS(250 μg/kg)1 hour after daily administration of the drug/normal saline to establish neuroinflammation model.Serum levels of IL-6 and TNF-α were measured 2 h after the last medication;histopathological morphology of cerebral tissue in mice were observed;the co-localization of inducible nitric oxide synthase(iNOS)/ionized calcium binding adapter molecule 1(Iba1)and CD206/Iba1 in the cerebral cortex region of mice was observed;the expressions of proteins related to the nuclear factor-κB(NF-κB)/mitogen-activated protein kinase(MAPK)signaling pathway in brain tissue of mice were also determined,including NF-κB p65,phosphorylated NF-κB p65(p-NF-κB p65),p38 MAPK,phosphorylated p38 MAPK(p-p38 MAPK),extracellular signal-regulated kinase(ERK),and phosphorylated ERK(p-ERK).RESULTS In the cell experiments,compared with control group,the levels of IL-6,TNF-α and NO in the cell supernatant of the LPS group were increased significantly(P<0.05);compared with LPS group,the levels of IL-6,TNF-α and NO were decreased significantly in the administration groups(P<0.05).In the animal experiments,compared with the normal group,the serum levels of IL-6 and TNF-α,the number of iNOS/Iba1 co-localization positive cells in the cerebral cortex,and the phosphorylation levels of p38 MAPK,NF-κB p65 and ERK proteins in brain tissue were all significantly increased/elevated in model group(P<0.05);the number of CD206/Iba1 co-localization positive cells in the cerebral cortex region significantly decreased(P<0.05).The neurons in the cerebral cortex and the CA3 region of the hippocampus displayed a disordered arrangement.Compared with model group,above quantitative indexes of mice were all reversed significantly in administration groups(P<0.05);the neuronal cells in the cerebral cortex and the CA3 region of the hippocampus exhibited a relatively orderly arrangement.CONCLUSIONS AS-Ⅳ may inhibit the activation of the NF-κB/MAPK signaling pathway,promote the M2-type polarization of microglia,and thereby suppress neuroinflammatory responses.
王咪咪;冯永岗;韩云;单凯欣;刘福宇;苗明三;方晓艳
河南中医药大学药学院,郑州 450046河南中医药大学药学院,郑州 450046河南中医药大学药学院,郑州 450046河南中医药大学药学院,郑州 450046河南中医药大学药学院,郑州 450046||驻马店市中心医院药学部,河南 驻马店 463000河南中医药大学药学院,郑州 450046||豫药全产业链研发河南省协同创新中心,郑州 450046河南中医药大学药学院,郑州 450046||豫药全产业链研发河南省协同创新中心,郑州 450046
医药卫生
黄芪甲苷小胶质细胞炎症表型极化神经保护
astragaloside Ⅳmicrogliainflammationphenotypic polarizationneuroprotection
《中国药房》 2026 (1)
30-35,6
国家自然科学基金项目(No.82274119)河南省重点研发专项(No.251111314100)河南省科技研发计划联合基金项目(No.222301420091)
评论